Journal article
A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89 Zr-immuno-PET agents
Dalton transactions : an international journal of inorganic chemistry, Vol.47(37), pp.13214-13221
09/04/2018
DOI: 10.1039/C8DT01841C
PMCID: PMC6192516
PMID: 30178793
Abstract
Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. This report describes a revised strategy that reduces preparation time while increasing the specific activity of clinically relevant immuno-PET agents. Additionally, it demonstrates that n-acetyl-l-cysteine acts as a superior radioprotective agent that improves long-term stability without compromising antigen affinity in vivo.
Details
- Title: Subtitle
- A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89 Zr-immuno-PET agents
- Creators
- Nikunj B Bhatt - Wake Forest UniversityDarpan N Pandya - Wake Forest UniversityStephanie Rideout-Danner - Wake Forest UniversityHoward D Gage - Wake Forest UniversityFrank C Marini - Wake Forest Institute for Regenerative MedicineThaddeus J Wadas - Wake Forest University
- Resource Type
- Journal article
- Publication Details
- Dalton transactions : an international journal of inorganic chemistry, Vol.47(37), pp.13214-13221
- DOI
- 10.1039/C8DT01841C
- PMID
- 30178793
- PMCID
- PMC6192516
- NLM abbreviation
- Dalton Trans
- ISSN
- 1477-9226
- eISSN
- 1477-9234
- Grant note
- DOI: 10.13039/100005562, name: North Carolina Biotechnology Center, award: 2016-BIG-6524; DOI: 10.13039/100006108, name: National Center for Advancing Translational Sciences, award: UL1TR001420
- Language
- English
- Date published
- 09/04/2018
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9984313074202771
Metrics
16 Record Views